Entrada Therapeutics (TRDA) Form 144: 6,422 Shares Planned for Sale

Q: How many Entrada Therapeutics (TRDA) shares are being registered for sale under this Form 144?

The filing covers 6,422 common shares valued at about USD 45,737.

Q: Who is the seller in the TRDA Form 144 filing?

The shares are being sold for the account of 5AM Opportunities I, L.P. , a venture investment fund.

Q: What percentage of Entrada Therapeutics鈥� outstanding shares does the proposed sale represent?

Approximately 0.02 % of the 37.95 million shares outstanding.

Q: Have there been recent sales by the same shareholder?

Yes. The fund sold 19,265 shares on 27 Jun 2025 and 6,422 shares on 30 Jun 2025, totaling 25,687 shares in three months.

[8-K] American Eagle Outfitters Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

On 1 July 2025, venture fund 5AM Opportunities I, L.P. filed a Form 144 indicating its intent to sell up to 6,422 common shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) through TD Securities (USA) LLC. The proposed transaction is valued at roughly USD 45,737 and represents only 0.02 % of Entrada鈥檚 37.95 million shares outstanding.

The filing also discloses that the same fund recently sold 19,265 shares on 27 Jun 2025 for USD 133,121 and 6,422 shares on 30 Jun 2025 for USD 43,751, bringing total sales in the past three months to 25,687 shares (鈮� 0.07 % of the float) for gross proceeds of approximately USD 176,872.

The shares were originally acquired on 29 Mar 2021 via a cash-financed venture investment. No operational, earnings, or strategic updates are provided in this notice. Form 144 merely gives advance notice of potential affiliate sales; execution is not assured. Given the small size relative to the public float, the filing is unlikely to materially affect liquidity or valuation but does indicate continued position trimming by an early investor.

Insights

TL;DR: Minor insider sale鈥�6.4k shares (0.02 %) planned; unlikely to move TRDA stock materially.

The filing signals a routine disposal of a modest stake by 5AM Opportunities I, L.P., following two similarly sized trades earlier in the week. Aggregate sales of 25.7k shares over three months are immaterial to Entrada鈥檚 37.9 million-share float and generate less than USD 0.2 million in proceeds鈥攏egligible versus the company鈥檚 market cap. No adverse operational information accompanies the notice, so the market impact should be neutral barring sentiment-driven reactions to continued venture-fund selling.

TL;DR: Routine affiliate filing; no governance red flags, impact minimal.

Form 144 compliance shows the seller is observing SEC disclosure rules. The representation statement affirms no undisclosed adverse information, and there is no indication of a 10b5-1 plan. The modest share count and voluntary disclosure timing suggest orderly liquidation rather than urgency or insider concern. From a governance perspective, this is a standard event with no material implications.

07/01/2025 - 05:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 25, 2025

AMERICAN EAGLE OUTFITTERS, INC.

(Exact name of registrant as specified in its charter)


Delaware	1-33338	13-2721761
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


77 Hot Metal Street
Pittsburgh, Pennsylvania		15203-2329
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (412) 432-3300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, $0.01 par value

AEO

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.07. Submission of Matters to a Vote of Security Holders.

On June 25, 2025, American Eagle Outfitters, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) by means of remote communication. As of May 1, 2025, the record date for the Annual Meeting, there were a total of 173,264,684 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 160,279,159 shares of Common Stock were represented in person by virtual participation or by proxy and, therefore, a quorum was present.

The stockholders of the Company voted on the following proposals:

1. To elect two Class III directors to serve until the Company’s 2028 Annual Meeting of Stockholders (“Proposal 1”);

2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 (“Proposal 2”); and

3. To approve, on an advisory basis, the fiscal 2024 compensation of our named executive officers (“Proposal 3”).

Proposal 1: Votes regarding the election of two Class III directors were as follows:


Name	For	Against	Abstain	Broker Non-Votes
Deborah A. Henretta	133,254,208	16,018,391	109,568	10,896,992
Cary D. McMillan	123,784,882	25,525,822	71,463	10,896,992

Based on the votes set forth above, each of Deborah A. Henretta and Cary D. McMillan were duly elected to serve as Class III directors until the Company’s 2028 Annual Meeting of Stockholders. The following persons continue to serve as Class I directors: Jay L. Schottenstein and Sujatha Chandrasekaran. The following persons continue to serve as Class II directors: Janice E. Page, David M. Sable, and Noel J. Spiegel.

Proposal 2: Votes regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 were as follows:


For	Against	Abstain	Broker Non-Votes
156,682,017	3,476,545	120,597	-

Based on the votes set forth above, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 was duly ratified.

Proposal 3: Votes regarding the approval, on an advisory basis, of the fiscal 2024 compensation of the Company’s named executive officers were as follows:


For	Against	Abstain	Broker Non-Votes
143,329,390	5,855,515	197,254	10,897,000

Based on the votes set forth above, the fiscal 2024 compensation of the Company’s named executive officers was approved on an advisory, non-binding basis.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	AMERICAN EAGLE OUTFITTERS, INC.
	(Registrant)

Date: July 1, 2025	By:	/s/ Beth M. Henke
		Beth M. Henke
		Executive Vice President and Chief Legal Officer

Source:

FAQ

How many Entrada Therapeutics (TRDA) shares are being registered for sale under this Form 144?

The filing covers 6,422 common shares valued at about USD 45,737.

Who is the seller in the TRDA Form 144 filing?

The shares are being sold for the account of 5AM Opportunities I, L.P., a venture investment fund.

What percentage of Entrada Therapeutics鈥� outstanding shares does the proposed sale represent?

Approximately 0.02 % of the 37.95 million shares outstanding.

Have there been recent sales by the same shareholder?

Yes. The fund sold 19,265 shares on 27 Jun 2025 and 6,422 shares on 30 Jun 2025, totaling 25,687 shares in three months.

Does the Form 144 filing guarantee that the shares will be sold?

No. Form 144 provides notice of intent; it does not oblige the seller to complete the transaction.

AG真人官方

[8-K] American Eagle Outfitters Reports Material Event

Insights

FAQ

How many Entrada Therapeutics (TRDA) shares are being registered for sale under this Form 144?

Who is the seller in the TRDA Form 144 filing?

What percentage of Entrada Therapeutics鈥� outstanding shares does the proposed sale represent?

Have there been recent sales by the same shareholder?

Does the Form 144 filing guarantee that the shares will be sold?

NYSE:AEO

AEO Rankings

AEO Latest News

AEO Latest SEC Filings

AEO Stock Data

AG真人官方

Trending News

[8-K] American Eagle Outfitters Reports Material Event

Insights

Securities Analyst neutral

Corporate Governance Expert neutral

FAQ

How many Entrada Therapeutics (TRDA) shares are being registered for sale under this Form 144?

Who is the seller in the TRDA Form 144 filing?

What percentage of Entrada Therapeutics鈥� outstanding shares does the proposed sale represent?

Have there been recent sales by the same shareholder?

Does the Form 144 filing guarantee that the shares will be sold?

NYSE:AEO

AEO Rankings

AEO Latest News

AEO Latest SEC Filings

AEO Stock Data